ID   SNU-2563CR
AC   CVCL_YD50
DR   cancercelllines; CVCL_YD50
DR   Wikidata; Q98132757
RX   CelloPub=CLPUB00546;
CC   Part of: Seoul National University (SNU) cell line collection.
CC   Population: Korean.
CC   Selected for resistance to: ChEBI; CHEBI_64310; Crizotinib (Xalkori).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (CelloPub=CLPUB00546).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_YD25 ! SNU-2563
SX   Male
AG   49Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 19-12-24; Version: 9
//
RX   CelloPub=CLPUB00546;
RA   Seo H.-Y.;
RT   "Establishment and characterization of 28 human lung cancer cell lines
RT   derived from pleural effusions.";
RL   Thesis MSc (2019); Seoul National University College of Medicine; Seoul; South Korea.
//